BMI 27 and Wegovy: What the Eligibility Rules Actually Say

The misconception: 'Wegovy is only for people with a BMI over 30'

This is the most common confusion around Wegovy eligibility, and it is understandable. The 30 figure gets repeated because that is the lower threshold for people without a weight-related health condition. But the UK product licence is clear on a second, lower threshold. Adults with a BMI of 27 to 29.9 who have at least one qualifying condition are within the licensed indication for semaglutide (Wegovy). The NHS medicines page for semaglutide sets this out plainly, as does the SmPC published on the electronic Medicines Compendium.

Qualifying conditions include type 2 diabetes, prediabetes, hypertension, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, and cardiovascular disease, among others assessed by the prescriber. If you have one of those and your BMI sits at 27, the licence does not rule you out. What matters is whether a prescriber, having reviewed your health in full, considers treatment appropriate for you specifically.

It is also worth knowing that BMI is a blunt instrument. The same number can represent very different metabolic risk profiles depending on body composition, family history and how weight is distributed. That context is exactly why clinical assessment exists, it considers the full picture that a number alone cannot capture. You can use the Wegovy BMI eligibility calculator as an initial sense-check, but a calculator replaces nothing about that review.

How BMI 27 sits within Wegovy's licensed eligibility in the UK

To be precise about the licensed thresholds: Wegovy is authorised in the UK for adults with a BMI of 30 or above, and separately for adults with a BMI of 27 to 29.9 where at least one weight-related comorbidity is present. The NICE appraisal of semaglutide (TA875) sits alongside the licence but applies to NHS prescribing specifically, it sets a higher threshold of BMI 35 or above (with a qualifying condition), within a specialist weight management service, for a maximum of two years. That NICE recommendation governs what the NHS commissions, not what is clinically licensed.

For a private prescription, the relevant bar is the licensed indication. A BMI of 27 with a qualifying condition falls within it. Whether treatment is right for you is a separate question, answered by a prescriber who can review your medical history, current medications and overall health. If you're curious how BMI 27 compares to higher thresholds, the page covering Wegovy eligibility at BMI 30 explains where those distinctions sit.

One practical note on timing: if you are planning to start a conversation with a prescriber, you do not need to wait for a Monday or the end of the month. Consultations are available any working day; the cut-off for same-day dispatch is 12pm, which is worth knowing if you are organising things around work or a busy week.

What a BMI just below the standard threshold means for your options

If your BMI is slightly below 27 (say, 25 or 26) the position changes. The licensed indication does not cover a BMI below 27 under any circumstances. The page on Wegovy and a BMI of 25 goes into this in more detail, including what the evidence says about using GLP-1 medicines outside licensed criteria and why responsible prescribers follow those boundaries. Similarly, if you're reviewing eligibility across the lower range, the BMI 26 and Wegovy page covers the adjacent scenario.

For those whose BMI is clearly above 30, the calculation is simpler, no comorbidity is needed to meet the licensed threshold. The overview on what BMI you need for Wegovy maps out the full picture across all the thresholds, which is a useful reference if you want everything in one place.

Wegovy is not the only licensed option for weight management in the UK. Tirzepatide (Mounjaro) carries a similar lower threshold of BMI 27 with a qualifying condition, and the two medicines work through different mechanisms, Wegovy acts on GLP-1 receptors alone, while tirzepatide activates both GLP-1 and GIP receptors. The weight-loss treatment overview covers both, with the evidence set out clearly. Which is more appropriate for you is part of what a prescriber considers.

How a prescriber decides, and what happens if you're borderline

Being within the licensed eligibility range does not automatically lead to a prescription. A GPhC-registered prescriber looks at contraindications, current medications, your history with weight-related conditions, and your goals. For Wegovy specifically, the prescriber will consider whether the qualifying condition is documented and current, and whether any contraindications apply, for example, a personal or family history of medullary thyroid carcinoma, or certain pancreatic conditions, would require a careful conversation.

The prescriber may also discuss what success looks like. NICE guidance notes that if less than 5% weight loss is achieved after six months on the maintenance dose, continuing treatment should be reviewed. That is not a threat, it is a sign that the prescriber is monitoring whether treatment is genuinely working for you, which is what good clinical oversight looks like.

The Wegovy treatment page covers the full eligibility and process in detail. If you want to understand cost before you start, the Wegovy price comparison page sets out what private treatment typically costs in the UK and what to look for when comparing providers. When you're ready to speak to a prescriber about whether Wegovy is right for a BMI of 27 with your specific health profile, start your free consultation with our clinical team.